세계의 신경계 질환용 디지털 바이오마커 시장 예측(-2032년) : 유형별, 적응증별, 임상 용도별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Digital Biomarkers for Neurological Conditions Market is accounted for $894.9 million in 2025 and is expected to reach $4638.6 million by 2032 growing at a CAGR of 26.5% during the forecast period. Digital biomarkers for neurological conditions are objective, quantifiable physiological and behavioral data collected through digital devices such as wearable sensors, mobile apps, or implantable technologies. These biomarkers capture changes in movement, cognition, speech, sleep, and other neurological functions, enabling continuous monitoring of disease progression, treatment response, and early detection of neurological disorders like Parkinson's, Alzheimer's, and multiple sclerosis. By integrating advanced analytics and artificial intelligence, digital biomarkers provide personalized insights, support clinical decision-making, and facilitate remote patient management, improving outcomes while reducing reliance on traditional, episodic clinical assessments.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

Neurodegenerative conditions across aging and at-risk populations are accelerating interest in non-invasive tracking tools. Mobile sensors, wearables, and AI-powered platforms are expanding diagnostic capabilities beyond traditional clinical settings. Integration with remote monitoring and telemedicine is fostering adoption across healthcare systems. Research institutions and medtech innovators are propelling real-time neurological data capture. These dynamics are expected to significantly boost the digital biomarkers for neurological conditions market.

Restraint:

Lack of standardization and validation

Fragmented protocols and inconsistent data pipelines limit cross-platform compatibility. Limited benchmarking is constraining multi-center trials and slowing global deployment. Healthcare providers face challenges in integrating diverse data streams into existing systems. Developers must invest in harmonization frameworks and robust validation pipelines to overcome these barriers. These limitations are expected to constrain the digital biomarkers for neurological conditions market.

Opportunity:

Shift toward personalized and preventive healthcare

Individualized tracking of cognitive and motor symptoms is reshaping patient engagement. Integration with mobile apps, cloud platforms, and wearable sensors is accelerating uptake in both clinical and consumer settings. Public health initiatives and employer wellness programs are fostering early adoption of cognitive and motor monitoring tools. Demand for proactive brain health management is propelling innovation in adaptive biomarker systems. These trends are expected to significantly boost the digital biomarkers for neurological conditions market.

Threat:

High development and implementation costs

Financial and technical demands restrict entry for emerging players. Specialized hardware, data infrastructure, and compliance requirements are degrading affordability and slowing deployment. Clinical validation and longitudinal studies demand substantial investment and operational capacity. Smaller players face barriers in accessing reimbursement and institutional partnerships. Such constraints are expected to hinder the digital biomarkers for neurological conditions market.

Covid-19 Impact:

The Covid-19 pandemic disrupted clinical trials and delayed deployment of digital biomarker technologies across neurological care pathways. Remote monitoring demand and virtual diagnostics adoption accelerated interest in sensor-based neurological tracking. Wearables and mobile platforms gained traction during lockdowns for cognitive and motor symptom surveillance. Hybrid care models and tele-neurology are expanding access to digital biomarker tools post-pandemic. Public health focus on mental resilience and long-term neurological effects is fostering investment in scalable solutions. These shifts are expected to propel the digital biomarkers for neurological conditions market.

The wearable devices segment is expected to be the largest during the forecast period

The wearable devices segment is expected to account for the largest market share during the forecast period due to rising neurological disorder prevalence and demand for continuous, real-world data capture. Smartwatches, biosensors, and motion trackers are driving clinical and consumer adoption. Hospitals, research centres, and home-care settings are expanding use for motor function, sleep, and cognitive monitoring. Integration with AI analytics and cloud platforms is fostering real-time decision support. Manufacturers are investing in multi-condition versatility and user-friendly formats. This segment is expected to significantly boost the digital biomarkers for neurological conditions market.

The Parkinson's disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Parkinson's disease segment is predicted to witness the highest growth rate drives demand for precise motor and cognitive tracking. Digital biomarkers are enabling early diagnosis, symptom progression monitoring, and therapy optimization in Parkinson's care. Wearables, voice analytics, and gait sensors are accelerating clinical research and patient engagement. Integration with remote care platforms and personalized treatment models is fostering adoption. Developers are focusing on scalable, validated tools tailored to Parkinson's-specific needs. This segment is expected to propel the digital biomarkers for neurological conditions market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by rising neurological disease burden and regional innovation. Rapid urbanization, aging demographics, and expanding digital health infrastructure are accelerating demand. China, India, Japan, and South Korea are scaling neurorehabilitation and cognitive wellness programs. Local manufacturing and competitive pricing are fostering widespread adoption. Government-backed initiatives in mental health and aging care are propelling market expansion. These dynamics are expected to significantly boost the Asia Pacific digital biomarkers for neurological conditions market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR propelled by neurological disorder prevalence and strong investment in brain health innovation. United States and Canada are integrating digital biomarkers into clinical trials, remote care, and personalized neurology platforms. Academic institutions and startups are fostering innovation in non-invasive tracking and AI-driven analytics. Regulatory support for digital health technologies is accelerating market penetration. Public-private partnerships and reimbursement expansion are driving adoption across healthcare systems. These developments are expected to propel the North America digital biomarkers for neurological conditions market.

Key players in the market

Some of the key players in Digital Biomarkers for Neurological Conditions Market include NeuraLight, MindMaze SA, Neuroelectrics, Emotiv Inc., NeuroPace, Inc., Kernel, Cognifit Inc., Posit Science Corporation, OpenBCI, Flow Neuroscience, BrainCo, Inc., Novela Neurotechnologies, BioSensics LLC, Aural Analytics, Inc. and Quantified Health.

Key Developments:

In September 2025, NeuraLight partnered with the CHDI Foundation to develop precision eye movement biomarkers for Huntington's disease. This collaboration aims to create sensitive, trial-ready tools to support clinical trials and therapeutic development for Huntington's disease.

In July 2025, NeuroX acquired the assets and operations of MindMaze, a recognized leader in digital neurotherapeutics. This acquisition aimed to enhance NeuroX's capabilities in providing disease-modifying motor and cognitive treatments for neurological diseases and brain disorders.

Types Covered:

• Wearable Devices
• Mobile Applications
• Sensors
• Software Platforms
• Data Analytics Tools
• Cloud-Based Platforms

Indications Covered:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Epilepsy
• Other Indication

Clinical Applications Covered:

• Diagnostic Biomarkers
• Monitoring Biomarkers
• Disease Progression Tracking
• Treatment Response Assessment
• Predictive Biomarkers
• Risk Assessment Models
• Prognostic Indicators

End Users Covered:

• Healthcare Providers
• Healthcare Companies
• Research Organizations

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Biomarkers for Neurological Conditions Market, By Type

• 5.1 Introduction
• 5.2 Wearable Devices
  • 5.2.1 Smartwatches
  • 5.2.2 Fitness Trackers
  • 5.2.3 Biosensors
• 5.3 Mobile Applications
• 5.4 Sensors
  • 5.3.1 EEG Sensors
  • 5.3.2 ECG Sensors
  • 5.3.3 Motion Sensors
• 5.5 Software Platforms
  • 5.5.1 Data Analytics Tools
  • 5.5.2 Cloud-Based Platforms

6 Global Digital Biomarkers for Neurological Conditions Market, By Indication

• 6.1 Introduction
• 6.2 Alzheimer's Disease
• 6.3 Parkinson's Disease
• 6.4 Multiple Sclerosis
• 6.5 Epilepsy
• 6.6 Other Indication

7 Global Digital Biomarkers for Neurological Conditions Market, By Clinical Application

• 7.1 Introduction
• 7.2 Diagnostic Biomarkers
• 7.3 Monitoring Biomarkers
  • 7.3.1 Disease Progression Tracking
  • 7.3.2 Treatment Response Assessment
• 7.4 Predictive Biomarkers
  • 7.4.1 Risk Assessment Models
  • 7.4.2 Prognostic Indicators

8 Global Digital Biomarkers for Neurological Conditions Market, By End User

• 8.1 Introduction
• 8.2 Healthcare Providers
  • 8.2.1 Hospitals
  • 8.2.2 Neurology Clinics
• 8.3 Healthcare Companies
  • 8.3.1 Pharmaceutical Companies
  • 8.3.2 Biotech Firms
• 8.4 Research Organizations
  • 8.4.1 Academic Institutions
  • 8.4.2 Clinical Research Organizations

9 Global Digital Biomarkers for Neurological Conditions Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 NeuraLight
• 11.2 MindMaze SA
• 11.3 Neuroelectrics
• 11.4 Emotiv Inc.
• 11.5 NeuroPace, Inc.
• 11.6 Kernel
• 11.7 Cognifit Inc.
• 11.8 Posit Science Corporation
• 11.9 OpenBCI
• 11.10 Flow Neuroscience
• 11.11 BrainCo, Inc.
• 11.12 Novela Neurotechnologies
• 11.13 BioSensics LLC
• 11.14 Aural Analytics, Inc.
• 11.15 Quantified Health